Palvella Therapeutics (PVLA) Other Non-Current Liabilities (2013 - 2026)

Palvella Therapeutics (PVLA) has 12 years of Other Non-Current Liabilities data on file, last reported at $2.2 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $2.2 million, up 25.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 25.26% YoY), and the FY2025 annual result was $2.0 million, up 23.92% from the prior year.
• Other Non-Current Liabilities climbed to $2.2 million in Q1 2026 per PVLA's latest filing, from $2.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $2.2 million in Q1 2026 and troughed at $1.0 million in Q4 2023.
• A 4-year average of $1.8 million and a median of $1.8 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities jumped 62.43% in 2024, then gained 23.92% in 2025.
• A 4-year view of Other Non-Current Liabilities shows it stood at $1.0 million in 2023, then jumped by 62.43% to $1.6 million in 2024, then increased by 23.92% to $2.0 million in 2025, then increased by 5.68% to $2.2 million in 2026.
• Business Quant data shows PVLA's Other Non-Current Liabilities at $2.2 million in Q1 2026, $2.0 million in Q4 2025, and $1.9 million in Q3 2025.